ClinicalTrials.Veeva

Menu

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Eisai logo

Eisai

Status and phase

Completed
Phase 1

Conditions

Pharmacokinetics in Obese Adolescents

Treatments

Drug: Lorcaserin

Study type

Interventional

Funder types

Industry

Identifiers

NCT02022956
APD356-025

Details and patient eligibility

About

The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old

Full description

The purpose is to:

  1. Assess the single-dose pharmacokinetic (PK) parameters of lorcaserin and a primary metabolites (M1 and M5) in obese adolescent subjects ages 12-17 (inclusive)
  2. Assess the safety and tolerability of a single oral dose of lorcaserin in obese adolescent subjects ages 12-17 (inclusive)

Enrollment

8 estimated patients

Sex

All

Ages

12 to 17 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Adolescent subjects aged 12 to 17 years, inclusive at screening

  2. a. Eligible female subjects who are sexually active will be:

    • non-pregnant
    • non-lactating
    • agree to continue to use an accepted method of birth control for at least 1 month after study medication administration
  3. BMI ≥ 95th percentile for age and gender, but ≤ 44 kg/m21

  4. Considered to be in stable health in the opinion of the Investigator.

  5. Parent or guardian who can sign written informed consent and subject willing to sign assent

Exclusion criteria

  1. Clinically significant new illness in the 1 month before screening and any time prior to randomization
  2. Significant renal or hepatic disease
  3. Secondary (chromosomal, endocrine, or metabolic) causes of obesity
  4. Use of medications other than hormonal contraceptives and acetaminophen
  5. Use of drugs with serotonergic activity within 1 month before screening
  6. Recent treatment with over-the-counter weight loss products or appetite suppressants, or within 3 months of screening and any time prior to randomization with a prescription weight loss drug or lipid dissolving injections or ongoing psychotherapy for weight loss outside of this trial
  7. Recent history of alcohol, tobacco, or recreational drug/solvent use
  8. Any history of major depression, anxiety, bipolar disorder, schizophrenia, or Axis II psychiatric disease requiring treatment with prescription medication within six months prior to screening

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

8 participants in 1 patient group

Open-Label Lorcaserin (BELVIQ)
Experimental group
Treatment:
Drug: Lorcaserin

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems